Nxera Pharma Co., Ltd.
Nxera Pharma Co., Ltd. (4565.T) Financial Performance & Income Statement Overview
Review Nxera Pharma Co., Ltd. (4565.T) income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Nxera Pharma Co., Ltd. (4565.T) Income Statement & Financial Overview
Review Nxera Pharma Co., Ltd. 4565.T income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $6.85B | $9.26B | $8.11B | $4.61B |
| Cost of Revenue | $2.13B | $2.99B | $3.31B | $2.17B |
| Gross Profit | $4.72B | $6.27B | $4.80B | $2.44B |
| Gross Profit Ratio | $0.69 | $0.68 | $0.59 | $0.53 |
| R&D Expenses | $3.30B | $3.03B | $2.32B | $3.16B |
| SG&A Expenses | $4.30B | $2.70B | $3.37B | $2.67B |
| Operating Expenses | $7.30B | $5.73B | $5.69B | $5.83B |
| Total Costs & Expenses | $9.43B | $8.72B | $9.00B | $8.004B |
| Interest Income | $0.00 | $252.00M | $415.00M | $465.00M |
| Interest Expense | $0.00 | $195.00M | $199.00M | $185.00M |
| Depreciation & Amortization | $1.003B | $994.00M | $1.004B | $983.00M |
| EBITDA | -$1.57B | $2.05B | $841.00M | -$1.62B |
| EBITDA Ratio | -$0.23 | $0.22 | $0.10 | -$0.35 |
| Operating Income | -$2.58B | $541.00M | -$888.00M | -$3.39B |
| Operating Income Ratio | -$0.38 | $0.06 | -$0.11 | -$0.74 |
| Other Income/Expenses (Net) | $208.00M | $324.00M | $526.00M | $597.00M |
| Income Before Tax | -$2.37B | $865.00M | -$362.00M | -$2.80B |
| Income Before Tax Ratio | -$0.35 | $0.09 | -$0.04 | -$0.61 |
| Income Tax Expense | -$1.03B | -$335.00M | $1.06B | $485.00M |
| Net Income | -$1.33B | $1.20B | -$1.42B | -$3.28B |
| Net Income Ratio | -$0.19 | $0.13 | -$0.18 | -$0.71 |
| EPS | -$14.86 | $13.35 | -$15.86 | -$36.68 |
| Diluted EPS | -$14.85 | $13.35 | -$15.86 | -$36.68 |
| Weighted Avg Shares Outstanding | $89.86M | $89.90M | $89.68M | $89.45M |
| Weighted Avg Shares Outstanding (Diluted) | $89.90M | $89.90M | $89.68M | $89.45M |
Over the last four quarters, Nxera Pharma Co., Ltd.'s revenue moved from $4.61B in Q1 2024 to $6.85B in Q4 2024. Operating income in Q4 2024 was -$2.58B, with a strong operating margin of -38%. Despite fluctuations in R&D and SG&A expenses, EBITDA for Nxera Pharma Co., Ltd. remained robust at -$1.57B, reflecting operational efficiency. Net income dropped to -$1.33B, with an EPS of -$14.86. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan